Skip to main content

Table 2 Different responses of Vancomycin HCl microspheres employed in Box–Behnken experimental design

From: DoE approach for development of localized controlled release microspheres of Vancomycin for treatment of septic arthritis

Formulation code Percentage yield (%) Particle size (Y1, µm) Entrapment efficiency (Y2, %) Drug release (Y3, %)
VMS 1 87.5 ± 0.12 18.26 ± 0.31 33.17 ± 0.32 68.04 ± 0.31
VMS 2 92 ± 0.20 12.92 ± 0.65 45.94 ± 0.12 74.10 ± 0.45
VMS 3 90 ± 0.40 4.44 ± 0.64 79.92 ± 0.42 88.02 ± 0.42
VMS 4 85.2 ± 0.31 5.02 ± 0.41 80.42 ± 0.44 84.03 ± 0.61
VMS 5 88.8 ± 0.12 10.23 ± 0.51 58.05 ± 0.51 80.29 ± 0.53
VMS 6 84.2 ± 0.32 14.20 ± 0.32 42.19 ± 0.23 74.30 ± 0.65
VMS 7 85 ± 0.4 6.29 ± 0.61 52.06 ± 0.11 82.02 ± 0.72
VMS 8 86.25 ± 0.51 20.28 ± 0.42 27.12 ± 0.61 69.50 ± 0.21
VMS 9 92.7 ± 0.26 11.50 ± 0.22 50.16 ± 0.32 76.02 ± 0.61
VMS 10 90.05 ± 0.42 15.09 ± 0.51 40.24 ± 0.61 72.32 ± 0.42
VMS 11 86.66 ± 0.61 8.26 ± 0.45 60.06 ± 0.51 78.31 ± 0.32
VMS 12 83.40 ± 0.51 7.89 ± 0.52 64.02 ± 0.21 81.3 ± 0.22
  1. Data are represented as mean ± SD (n = 3)
  2. VMS Vancomycin HCl microspheres